We show that knockdown of IRF7 is sufficient to abolish the type-1 IFN response to both the selective TLR4 agonist LPS and the indiscriminate TLR ligand Aβ1-42 in human neuroblastoma M17 BE(2) cells. This evidence concerns the gene IRF7 and neuroblastoma.